

# Ulrike Schmidt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8267691/publications.pdf>

Version: 2024-02-01

35  
papers

2,027  
citations

361413

20  
h-index

395702

33  
g-index

35  
all docs

35  
docs citations

35  
times ranked

3576  
citing authors

#	ARTICLE	IF	CITATIONS
1	FK506-binding Proteins 51 and 52 Differentially Regulate Dynein Interaction and Nuclear Translocation of the Glucocorticoid Receptor in Mammalian Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 4609-4616.	3.4	545
2	Polymorphism in Tmem132d regulates expression and anxiety-related behavior through binding of RNA polymerase II complex. <i>Translational Psychiatry</i> , 2018, 8, 1.	4.8	263
3	FK506 Binding Protein 5 Shapes Stress Responsiveness: Modulation of Neuroendocrine Reactivity and Coping Behavior. <i>Biological Psychiatry</i> , 2011, 70, 928-936.	1.3	235
4	Reduced hippocampus volume in the mouse model of Posttraumatic Stress Disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 650-659.	3.1	103
5	Biomarkers in Posttraumatic Stress Disorder: Overview and Implications for Future Research. <i>Disease Markers</i> , 2013, 35, 43-54.	1.3	85
6	Posttraumatic Growth in Populations with Posttraumatic Stress Disorder—A Systematic Review on Growth-Related Psychological Constructs and Biological Variables. <i>Clinical Psychology and Psychotherapy</i> , 2016, 23, 469-486.	2.7	84
7	The brain as immunoprecipitator of serum autoantibodies against N-methyl-D-aspartate receptor subunit NR1. <i>Annals of Neurology</i> , 2016, 79, 144-151.	5.3	75
8	Identification and characterization of HPA-axis reactivity endophenotypes in a cohort of female PTSD patients. <i>Psychoneuroendocrinology</i> , 2015, 55, 102-115.	2.7	74
9	Stress-primed secretory autophagy promotes extracellular BDNF maturation by enhancing MMP9 secretion. <i>Nature Communications</i> , 2021, 12, 4643.	12.8	50
10	Therapeutic Action of Fluoxetine is Associated with a Reduction in Prefrontal Cortical miR-1971 Expression Levels in a Mouse Model of Posttraumatic Stress Disorder. <i>Frontiers in Psychiatry</i> , 2013, 4, 66.	2.6	47
11	Essential Role of the Unusual DNA-binding Motif of BAG-1 for Inhibition of the Glucocorticoid Receptor. <i>Journal of Biological Chemistry</i> , 2003, 278, 4926-4931.	3.4	46
12	Epigenetic Aspects of Posttraumatic Stress Disorder. <i>Disease Markers</i> , 2011, 30, 77-87.	1.3	46
13	Long-Lasting Hippocampal Synaptic Protein Loss in a Mouse Model of Posttraumatic Stress Disorder. <i>PLoS ONE</i> , 2012, 7, e42603.	2.5	42
14	The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders. <i>Current Molecular Pharmacology</i> , 2015, 9, 126-140.	1.5	33
15	Searching for non-genetic molecular and imaging PTSD risk and resilience markers: Systematic review of literature and design of the German Armed Forces PTSD biomarker study. <i>Psychoneuroendocrinology</i> , 2015, 51, 444-458.	2.7	29
16	miRNAs and other non-coding RNAs in posttraumatic stress disorder: A systematic review of clinical and animal studies. <i>Journal of Psychiatric Research</i> , 2015, 65, 1-8.	3.1	28
17	Integrating NIMH Research Domain Criteria (RDoC) into PTSD Research. <i>Current Topics in Behavioral Neurosciences</i> , 2017, 38, 69-91.	1.7	28
18	A role for synapsin in FKBP51 modulation of stress responsiveness: Convergent evidence from animal and human studies. <i>Psychoneuroendocrinology</i> , 2015, 52, 43-58.	2.7	26

#	ARTICLE	IF	CITATIONS
19	New insights into the intracellular distribution pattern of cationic amphiphilic drugs. Scientific Reports, 2017, 7, 44277.	3.3	21
20	Molecular and neurocircuitry mechanisms of social avoidance. Cellular and Molecular Life Sciences, 2021, 78, 1163-1189.	5.4	21
21	Epigenetic aspects of posttraumatic stress disorder. Disease Markers, 2011, 30, 77-87.	1.3	21
22	A plea for symptom-based research in psychiatry. HÅrgrre Utbildning, 2015, 6, 27660.	3.0	20
23	Intranasally Applied Neuropeptide S Shifts a High-Anxiety Electrophysiological Endophenotype in the Ventral Hippocampus towards a "Normal"-Anxiety One. PLoS ONE, 2015, 10, e0120272.	2.5	20
24	The Dissociative Subtype of PTSD Interview (DSP-I): Development and Psychometric Properties. Journal of Trauma and Dissociation, 2019, 20, 564-581.	1.9	17
25	PTSD psychotherapy improves blood pressure but leaves HPA axis feedback sensitivity stable and unaffected: First evidence from a pre-post treatment study. Psychoneuroendocrinology, 2019, 100, 254-263.	2.7	16
26	The Hypothalamic-Pituitary-Adrenal Axis in Depression: Molecular Regulation, Pathophysiological Role, and Translational Implications. , 2019, , 89-96.		10
27	Digital psychological first aid for Ukraine. Lancet Psychiatry,the, 2022, 9, e33.	7.4	9
28	Oxytocin receptor is a potential biomarker of the hyporesponsive HPA axis subtype of PTSD and might be modulated by HPA axis reactivity traits in humans and mice. Psychoneuroendocrinology, 2021, 129, 105242.	2.7	7
29	MMP9 mRNA is a potential diagnostic and treatment monitoring marker for PTSD: Evidence from mice and humans. European Neuropsychopharmacology, 2021, 51, 20-32.	0.7	6
30	Analysis of the cerebellar molecular stress response led to first evidence of a role for FKBP51 in brain FKBP52 expression in mice and humans. Neurobiology of Stress, 2021, 15, 100401.	4.0	6
31	Azidobupramine, an Antidepressant-Derived Bifunctional Neurotransmitter Transporter Ligand Allowing Covalent Labeling and Attachment of Fluorophores. PLoS ONE, 2016, 11, e0148608.	2.5	5
32	Robustly High Hippocampal BDNF levels under Acute Stress in Mice Lacking the Full-length p75 Neurotrophin Receptor. Pharmacopsychiatry, 2021, 54, 205-213.	3.3	5
33	Posttraumatic growth during cognitive behavioural therapy for posttraumatic stress disorder: Relationship to symptom change and introduction of significant other assessment. Stress and Health, 2019, 35, 617-625.	2.6	3
34	Novel treatment targets for COVID-19: Contribution from molecular psychiatry. World Journal of Biological Psychiatry, 2020, 21, 572-575.	2.6	1
35	Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases. Therapeutic Advances in Psychopharmacology, 2015, 5, 208-213.	2.7	0